Get started
Repligen CorporationRepligen CorporationRepligen Corporation

Repligen Corporation

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

RGEN chart


Full chart

RGEN upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪8.23 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.15 USD
Net income (FY)
‪35.60 M‬ USD
Revenue (FY)
‪632.36 M‬ USD
Shares float
‪52.13 M‬
Beta (1Y)
0.36

Employees


Employees (FY)
‪1.78 K‬
Change (1Y)
−242 −11.95%
Revenue / Employee (1Y)
‪354.66 K‬ USD
Net income / Employee (1Y)
‪19.96 K‬ USD

About Repligen Corporation


Sector
Health Technology
CEO
Olivier Dominique Loeillot
Headquarters
Waltham
Website
repligen.com
Founded
1981
FIGI
BBG000BS48J3
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

RGEN news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

RGEN highest yielding bonds


RGEN5964422
Repligen Corporation 1.0% 15-DEC-2028
Yield to maturity
−0.53%
Maturity date
Dec 15, 2028

Explore more bonds 

Frequently Asked Questions


The current price of RGEN is 146.95 USD — it has increased by 0.89% in the past 24 hours. Watch Repligen Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Repligen Corporation stocks are traded under the ticker RGEN.
RGEN stock has fallen by −8.12% compared to the previous week, the month change is a 4.16% rise, over the last year Repligen Corporation has showed a −20.18% decrease.
We've gathered analysts' opinions on Repligen Corporation future price: according to them, RGEN price has a max estimate of 225.00 USD and a min estimate of 160.00 USD. Watch RGEN chart and read a more detailed Repligen Corporation stock forecast: see what analysts think of Repligen Corporation and suggest that you do with its stocks.
RGEN reached its all-time high on Sep 23, 2021 with the price of 327.32 USD, and its all-time low was 0.50 USD and was reached on Jul 15, 1996. View more price dynamics on RGEN chart.
See other stocks reaching their highest and lowest prices.
RGEN stock is 3.74% volatile and has beta coefficient of 0.36. Track Repligen Corporation stock price on the chart and check out the list of the most volatile stocks — is Repligen Corporation there?
Today Repligen Corporation has the market capitalization of ‪8.23 B‬, it has decreased by −7.90% over the last week.
Yes, you can track Repligen Corporation financials in yearly and quarterly reports right on TradingView.
Repligen Corporation is going to release the next earnings report on Feb 19, 2025. Keep track of upcoming events with our Earnings Calendar.
RGEN earnings for the last quarter are 0.43 USD per share, whereas the estimation was 0.34 USD resulting in a 28.22% surprise. The estimated earnings for the next quarter are 0.41 USD per share. See more details about Repligen Corporation earnings.
Repligen Corporation revenue for the last quarter amounts to ‪150.76 M‬ USD, despite the estimated figure of ‪153.02 M‬ USD. In the next quarter, revenue is expected to reach ‪167.66 M‬ USD.
RGEN net income for the last quarter is ‪−654.00 K‬ USD, while the quarter before that showed ‪5.71 M‬ USD of net income which accounts for −111.45% change. Track more Repligen Corporation financial stats to get the full picture.
No, RGEN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has ‪1.78 K‬ employees. See our rating of the largest employees — is Repligen Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Repligen Corporation EBITDA is ‪116.46 M‬ USD, and current EBITDA margin is 21.42%. See more stats in Repligen Corporation financial statements.
Like other stocks, RGEN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Repligen Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Repligen Corporation technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Repligen Corporation stock shows the sell signal. See more of Repligen Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.